Month: October 2026

Utility Specialists and Elgin B. Robertson extend coverage across Southeast and South Central U.S. through performance-based sales relationships

BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) — NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), through its wholly owned subsidiary NOMAD Transportable Power Systems, a manufacturer of transportable, utility-grade lithium iron phosphate (LFP) battery energy storage systems, today announced the appointment of Utility Specialists, Inc. (“USI”) and Elgin B. Robertson, Inc. (“EBR”) as independent sales representatives. The appointments expand NOMAD’s utility sales network to four representative firms covering 26 states and Washington, D.C.

USI, based in Birmingham, Alabama, will represent NOMAD in Alabama, Florida, Georgia, Mississippi, North Carolina, South Carolina, and Tennessee. EBR, headquartered in Dallas, Texas, will cover Texas, Oklahoma, and New Mexico. The firms will identify and develop opportunities for NOMAD’s Voyager Eagle, Voyager Falcon, and Voyager Hawk systems among utilities, municipalities, data center developers and operators, electrical contractors, and other industrial customers in their territories.

The new representatives join First Line Associates, which covers the Northeast and Mid-Atlantic (Connecticut, Delaware, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, and Washington, D.C.), and Peterson Company, which covers the Mountain West (Colorado, Idaho, Montana, Utah, and Wyoming) from its offices in Denver and Salt Lake City. Together, the four firms have 43 utility sales professionals expanding NOMAD’s access to established customer relationships across these territories. The agreements are performance-based, with representative compensation tied to sales and no fixed representative fees.

“USI and EBR bring longstanding utility relationships and experience helping customers evaluate and specify new equipment,” said Jim Allan, Director of Sales at NOMAD Transportable Power Systems. “These appointments expand our ability to reach customers facing grid constraints, infrastructure upgrades, and temporary power needs. Our in-house sales team will support the representatives with product expertise and demonstrations to help develop opportunities across their territories.”

Founded in 1957, USI has represented electric utility equipment manufacturers throughout the Southeast for nearly seven decades, serving investor-owned, municipal, and cooperative utilities, as well as electrical contractors, consultants, and distributors. Established in 1928, EBR serves the electric utility industry across Texas, Oklahoma, and New Mexico, with expertise in transmission, substation, and distribution applications.

“NOMAD’s transportable battery systems fill a real gap for the utilities and industrial customers we call on. They can put megawatt-scale power on site in under an hour, without the permitting and lead time of a permanent installation,” said Murray Beck, President of Utility Specialists, Inc. “We look forward to introducing NOMAD’s systems to our network across the Southeast.”

“Utilities in Texas, Oklahoma, and New Mexico are managing rapid load growth, storm restoration, and long interconnection timelines at the same time. NOMAD’s transportable systems give them a way to put megawatt-scale capacity where it is needed without waiting on a permanent installation,” said Zach Nichols, President of Elgin B. Robertson, Inc. “We are pleased to add NOMAD to our Power Utility line card.”

Supporting Utility and Industrial Power Needs

The expanded territories include markets where utilities are planning for increased electricity demand from data centers and industrial development. NOMAD is targeting applications including temporary power support during infrastructure upgrades, backup power, and peak-demand management.

NOMAD’s Voyager systems are designed to be deployed where needed and relocated as customer requirements change, allowing customers to use the same equipment across multiple locations and applications.

“The performance-based structure of these relationships allows us to broaden our sales reach while limiting fixed selling costs,” Allan added. “Our focus is on helping these firms identify applications where mobile power can address a specific customer need and supporting them through the sales process.”

The ten states covered by USI and EBR sit at the center of U.S. electricity demand growth. In Texas, ERCOT reported approximately 438 gigawatts (GW) of large-load interconnection requests as of May 2026, much of it tied to data centers.¹ Southern Company, whose utilities serve Alabama, Georgia, and Mississippi, has reported approximately 75 GW of data center interest in connecting to its system, including 10 GW under contract, and has raised its 2026–2030 capital plan to approximately $81 billion.² In Georgia alone, the prospective large-load pipeline grew from 16 GW in 2023 to approximately 69 GW by December 2025, according to Georgia Public Service Commission staff.³ Duke Energy, the largest utility in the Carolinas, reported 7.6 GW of executed data center agreements and a 15.4 GW data center pipeline in May 2026, supported by a $103 billion capital plan,⁴ and the Tennessee Valley Authority has reported 11 GW of data center requests.⁵ Nationally, Grid Strategies projects 166 GW of new electricity load by 2030.⁶

Much of this demand will arrive before the permanent generation, substations, and transmission needed to serve it are in place. NOMAD’s transportable systems are built to bridge that gap: bridging interconnection delays for new data center and industrial load, supporting utilities through substation and distribution upgrades, and providing backup and peak capacity that can be redeployed as needs change, either structurally or seasonally, depending on where the demand is over the long term.

Fall Demonstration Tour Update

NOMAD is supporting its sales efforts with a fall demonstration tour announced on October 6, 2026, including 26 stops across three regional roadshows. The tour included events with Peterson Company in Utah and Idaho on October 6–8 and First Line Associates across New England and the Mid-Atlantic on October 13–26.

The Southwest roadshow is scheduled for November 2–16, with stops in California, Nevada, Arizona, and New Mexico, including Albuquerque within EBR’s territory. NOMAD also plans a demonstration with USI in the Southeast, with dates and locations to be announced.

About NOMAD Power Solutions, Inc.

NOMAD Power Solutions, Inc. (Nasdaq: NMAD) is an energy infrastructure equipment and services company focused on the design, manufacture and deployment of transportable, utility-grade power and energy-storage systems. Through its NOMAD Transportable Power Systems subsidiary, the Company markets its systems under the Voyager platform. NOMAD’s systems are engineered to provide rapidly deployable, relocatable power capacity for utility, commercial, industrial and other applications where grid capacity is unavailable, constrained or uneconomical. For more information, visit www.nomadpower.com.

About Utility Specialists, Inc.

Utility Specialists, Inc. is a manufacturers’ representative firm based in Birmingham, Alabama, providing electric utility market contact, approval, sales, and long-term customer support since 1957. USI represents more than thirty manufacturers across the distribution, transmission, substation, lighting, metering, tools and equipment, and generation segments of the electric utility industry, serving investor-owned, municipal, and cooperative utilities, electrical contractors, consultants, and distributors throughout Alabama, Florida, Georgia, Mississippi, North Carolina, South Carolina, and Tennessee. For more information, visit utility-specialists.com.

About Elgin B. Robertson, Inc.

Elgin B. Robertson, Inc. is a Texas-based manufacturers’ representative firm established in 1928 and headquartered in Dallas. EBR represents manufacturers in the electric utility, communications, and CATV/MSO markets, providing Power Utility solutions for transmission, substation, and distribution applications throughout Texas, Oklahoma, and New Mexico. For more information, visit elginbrobertson.com.

Market Data Sources

¹ ERCOT Board of Directors presentation, May 2026, as reported by New Project Media: newprojectmedia.com/?p=19583

² Southern Company fourth-quarter 2025 earnings, February 18, 2026, as reported by Pipeline & Gas Journal: pgjonline.com/news/2026/february/southern-co-expands-81-billion-spending-plan-as-data-center-demand-drives-gas-generation-growth

³ Georgia Public Service Commission staff large-load report, as reported by WTOC, March 17, 2026: wtoc.com/2026/03/17/georgia-psc-chairman-defends-data-center-power-expansion-amid-criticism

⁴ Duke Energy first-quarter 2026 earnings, May 5, 2026, as reported by Utility Dive: utilitydive.com/news/duke-energy-earnings-anderson-gas-plant/819428

⁵ Tennessee Valley Authority, as reported by Louisville Public Media, August 20, 2026: lpm.org/news/2026-08-20/tva-will-consider-a-new-electricity-rate-for-data-centers-this-week

⁶ Grid Strategies, National Load Growth Report 2025: gridstrategiesllc.com/project/load-growth-forecast

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical fact, including statements regarding NOMAD’s beliefs, expectations, plans, and intentions relating to its sales representative relationships with USI, EBR, First Line Associates, and Peterson Company, the timing and locations of planned demonstration tours, the potential benefits, applications, market opportunity, and future development of its transportable battery energy storage systems, and future customer demand, the size of and demand within its target markets, future backlog growth, are forward-looking statements. These statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,” “will,” “plan,” “potential,” and similar expressions. Forward-looking statements are subject to risks and uncertainties, many of which are beyond NOMAD’s control, that could cause actual results to differ materially from those expressed or implied, including risks related to the performance of independent sales representatives; market acceptance and adoption of transportable energy storage technology; customer purchasing and deployment decisions; competition; the accuracy of third-party market data and load-growth forecasts; supply chain and manufacturing execution; and other risks described in NOMAD Power Solutions’ filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. NOMAD Power Solutions undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Investor Contact

Todd Kehrli or Michael Wichman
PondelWilkinson Inc.
tkehrli@pondel.com | MWichman@pondel.com 

Dollar share rose 11 points to approximately 33% over the same period, with growth accelerating in every measured window

Pizzolato delivered four of the five largest dollar-gaining items in U.S. organic sparkling wine while still early in its national distribution

SANTA MARIA, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) — AMASS Brands Inc. (Nasdaq: AMSS) (“AMASS” or “the Company”), a premium, multi-category beverage platform spanning non-alcohol, functional, and alcohol 2.0 products, today announced that Pizzolato, the Company’s organic sparkling wine brand, widened its lead as America’s No. 1 organic sparkling wine brand. Pizzolato held the top position across every measured period, and its retail sales growth accelerated in each successively shorter measurement window.¹

Pizzolato Highlights

• Widening Category Leadership. #1 organic sparkling wine brand in the U.S. across the latest 4, 13, 26 and 52 weeks, with approximately 29% dollar share over the latest 52 weeks, up 3.5 points year-over-year, rising to approximately 33% in the latest four weeks, up 10.9 points.¹
• Accelerating Growth. Retail dollar sales grew 15% over the latest 52 weeks, 16% over 26 weeks, 33% over 13 weeks and approximately 61% in the latest four weeks.¹
• Leading the Category’s Gains. Four of the five largest dollar-gaining items in U.S. organic sparkling wine over the latest 52 weeks were Pizzolato products. ¹
• Broad-Based Portfolio. Six Pizzolato items grew by double digits in retail sales over the latest 52 weeks.¹
• Taking Share in Single-Serve. Pizzolato’s 187mL minis grew 25% over the latest 52 weeks while the U.S. sparkling wine minis segment declined 2.1%.¹
• Expanding National Footprint. Pizzolato is sold in more than 4,000 retail accounts nationally, including Whole Foods Market nationwide, H-E-B, Safeway, The Fresh Market and Natural Grocers.²

Pizzolato is one of AMASS’ Core Brands, which grew preliminary net revenue approximately 67% in the third quarter of 2026, as previously reported on October 6, 2026.

“Pizzolato heads into the holidays, sparkling wine’s biggest season of the year, with its growth accelerating and its lead widening,” said Mark Thomas Lynn, Founder and Chief Executive Officer of AMASS. “Leading the category and gaining share as demand peaks is the kind of momentum we are concentrating our capital and commercial resources behind.”

¹ Source: NielsenIQ retail scan data, Total U.S. xAOC + Liquor + Convenience, latest 4, 13, 26 and 52 weeks ended October 3, 2026. Rankings, share and growth are measured within the U.S. organic sparkling wine category, except minis rankings and growth, which are measured among U.S. sparkling wine brands in the 187mL format. Growth rates compare to the same period one year prior. Retail scan data reflects consumer purchases at measured retailers and does not represent Company net revenue.

² Source: Company data, as of October 23, 2026.

About AMASS Brands Inc.

AMASS Brands, Inc. (Nasdaq: AMSS) is a next-generation beverage platform built around the brands defining how modern consumers drink, and increasingly, how they don’t. The company’s portfolio spans non-alcohol, functional, and alcohol 2.0 categories, with standout brands across each: Good Twin Non-Alcoholic Wine, a top non-alcoholic wine in the U.S. and one of the fastest-growing in the category; AMASS Electrolytes, a functional disruptor redefining the hydration category; and Pizzolato, the #1 organic sparkling wine in the U.S., among others across the portfolio. As moderation trends accelerate, AMASS is positioned to benefit structurally rather than reactively, with margin discipline, cohesive brand architecture, and the multi-brand scalability that supports the Company’s long-term brand and platform growth strategy.

Follow AMASS on LinkedIn

Follow AMASS on Instagram

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, brand portfolio, distribution expansion, retail sales growth, and the allocation of capital and commercial resources. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including: the fact that third-party retail scan data reflects consumer purchases at measured retailers and does not represent the Company’s net revenue; changes in consumer demand and competitive conditions; the Company’s ability to expand and maintain distribution; the substantial doubt regarding the Company’s ability to continue as a going concern; the Company’s need to raise additional capital and the terms on which that capital may be available; and the factors described under “Risk Factors” in the Company’s Prospectus dated June 29, 2026 (File No.: 333-297139) and subsequent SEC filings. The Company undertakes no obligation to update these statements except as required by law.

Investor Relations Contact

KCSA Strategic Communications
Rob Kelly, Vice President
(212) 896-1254
AMASS@KCSA.com

The Company defines initial regulatory screening capabilities as part of its broader AI-powered food formulation initiative

ROSH HAAYIN, Israel, Oct. 28, 2026 (GLOBE NEWSWIRE) — Ultrobotix Ltd. (CSE: UBTX) (the “Company”) announced today that it is advancing the development of its AI Food Technologist initiative, an internally developed artificial intelligence technology intended to assist food industry professionals with food and beverage formulation, ingredient analysis, product optimization and selected regulatory screening tasks.

The initiative builds upon the Company’s existing experience in food and beverage product development and is intended to combine food technology expertise with artificial intelligence to support more efficient formulation and product development processes.

Ultrobotix intends to develop AI capabilities that support food and beverage formulation, ingredient selection, product optimization and related product development workflows.

Progress Toward Proof of Concept

As part of this broader development strategy, the Company is preparing a focused proof of concept (“POC”) to evaluate selected regulatory screening capabilities of its proposed AI Food Technologist platform.

The regulatory screening POC represents a defined initial component of the Company’s broader AI development initiative and is intended to assess specific technical capabilities before determining whether further development and broader applications are warranted.

The proposed POC is expected to evaluate the AI agent’s ability to:

1. Analyze Formulations

Receive, interpret and structure ingredient lists and formulation data for further analysis.

2. Screen Regulatory Requirements

Identify selected ingredient restrictions, permitted uses and concentration limits applicable to food and beverage formulations in the United States, European Union and Israel.

3. Identify Ingredient Alternatives

Explore potential substitute ingredients where regulatory restrictions or formulation constraints are identified.

4. Support Product Development Workflows

Provide structured information intended to assist food technologists and product developers in evaluating formulations and potential product adjustments.

The proposed Ai food agent is intended to function as a decision-support tool for food developers, regulatory specialists or other food industry professionals.

Planned POC Evaluation

The Company intends to conduct an initial controlled evaluation in Israel using selected formulation scenarios and professional review of the AI agent’s outputs.

The evaluation is expected to focus on technical feasibility, response accuracy, consistency, practical usefulness and identification of limitations requiring further development.

The Company outlined plans to initiate a limited proof-of-concept activities during the fourth quarter of 2026. for the initial evaluation of the regulatory screening POC.

As the Company’s AI development activities progress, Ultrobotix is further defining the technical scope and sequencing of its proposed evaluations.

The timing and scope of the Company’s broader development and pilot activities remain subject to ongoing technical assessment, operational requirements and available financial resources.

Alignment with the Company’s AI Development Strategy

The regulatory screening POC forms part of the Company’s broader objective of developing AI-assisted tools for food and beverage formulation and product development.

The Company’s longer-term development objectives include supporting food industry professionals with ingredient analysis, formulation development, product optimization and related workflows.

The proposed regulatory screening functionality is intended to complement these broader objectives by helping identify potential regulatory considerations during the product development process.

Potential Applications and Next Steps

The proposed technology may have potential applications in food manufacturing, product development and formulation review, particularly for manufacturers evaluating products intended for multiple geographic markets.

Following the initial POC evaluation, the Company intends to review the results, assess identified technical limitations and determine whether further development, testing or potential commercial applications are warranted.

The initiative remains at an early stage of development. There can be no assurance that the proposed POC will achieve its intended objectives, that the AI technology will be successfully developed or that commercial applications will result.

Management Commentary

“Food product development involves complex formulation and regulatory decisions, particularly for products intended for multiple international markets,” said Elad Barkan, Chief Technology Officer of Ultrobotix.

“Our objective is to determine whether an AI agent can provide food technologists with faster access to structured formulation and regulatory information. Advancing toward a proof of concept is an important step in evaluating the initiative’s technical feasibility and potential practical value.”

About Ultrobotix Ltd.

Ultrobotix Ltd. is a food technology company focused on the development of innovative food and beverage products. The Company is developing an AI agent designed to assist food scientists, technologists, chefs, and product developers in the creation and optimization of food and beverage formulations. The agent is being developed to autonomously analyze ingredient functionality, nutritional targets, sensory profiles, regulatory requirements, and manufacturing parameters in order to generate and optimize product formulations. The Company has also established a division focused on robotics solutions through collaborations with third-party manufacturers of existing technologies. This division is intended to leverage the Company’s existing relationships within the food, hospitality, and service industries and is engaged in the marketing and commercialization of robotic technology solutions designed to support automation, operational efficiency, and scalable service delivery across these environments.

On behalf of Ultrobotix :

Yoav Bar-Joseph, CEO

Email: info@ultrobotix.com

Tel: +1 (786) 322 6055

Cautionary Statement

This news release contains “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities legislation. All statements included herein, other than statements of historical fact, may constitute forward-looking information or forward-looking statements.

Generally, forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects”, “anticipates”, “intends”, “believes”, or “will continue”, or variations of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Forward-looking statements in this news release include, but are not limited to, statements relating to: the potential future operations of Ultrobotix Ltd. (“Ultrobotix” or the “Company”); the anticipated benefits of its exploratory collaboration with food developers and food manufacturer; the anticipated involvement ,the identification and evaluation of Ai food agent for food developing applications; the potential introduction of Ai food agent solutions into food production facilities; the possible development and implementation of POC project; the potential to enter into future commercial agreements; and the potential expansion of the Company’s Ai food agent activities within the food development and manufacturing industry.

These forward-looking statements are based on management’s assumptions as at the date hereof, including assumptions that Ultrobotix will have or be able to obtain the necessary financial and operational resources to pursue its Ai food agent activities; that suitable artificial intelligence technologies may be available; that the Company will be able to continue gathering operational information and assessing the food developing and regulatory requirements; that the demand for Ai agents solutions within the food developing and manufacturing industry will develop in accordance with management’s expectations; and that the Company may be able to identify commercially viable opportunities.

Forward-looking information and forward-looking statements, while based on management’s current estimates, expectations and assumptions, are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Ultrobotix to differ materially from those expressed or implied by such forward-looking information or forward-looking statements.

These risks include, but are not limited to: the preliminary and exploratory nature of the proposed activities; the absence of binding commitments for the purchase, installation or deployment of Ai food agent technologies; the possibility that the Ai food agent that the company intend to develop may not meet the operational requirements of the food industry; technical, operational, safety and regulatory challenges associated with introducing Ai food agent technologies into food manufacturing environments; the availability of financial and operational resources; reliance on third-party technology providers and manufacturers; the possibility that proposed evaluations or proof of concept projects may not proceed or achieve satisfactory results; the inability to secure definitive commercial agreements; and other risk factors described in Ultrobotix’s public disclosure documents filed on its SEDAR+ profile at www.sedarplus.ca.

There can be no assurance that the proposed prof of concept and Ai food agent evaluation or pilot project will proceed, that any Ai food Agent will be purchased, installed or commercially deployed, or that the activities described in this news release will result in commercial agreements, business expansion or revenue for the Company.

Although Ultrobotix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information and forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.

There can be no assurance that such information or statements will prove to be accurate, as actual results and future events could differ materially from those anticipated.

The forward-looking statements and forward-looking information are made as of the date hereof, and Ultrobotix disclaims, except as required by applicable securities laws, any obligation to update or revise any forward-looking statements or forward-looking information contained herein to reflect future results, events or circumstances.

Accordingly, readers should not place undue reliance on forward-looking statements and information.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Human Research Ethics Submission Deadline Nov ‘26 with Site Initiation Activities Followed by First Patient Screening Planned for Feb ‘27

MELBOURNE, Australia, Oct. 28, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced it is advancing its clinical development program for PRP (Company Code Name: PPC-001, Propanc Proenzyme Combination) its investigational proenzyme-based therapeutic candidate, as the Company preparations continue for its planned Phase 1b, First-In-Human study in up to 50 advanced cancer patients with solid tumors. Several key workstreams are underway, including clinical trial protocol development, preparation of the Investigator’s Brochure (IB), clinical site feasibility assessments, vendor selection, and regulatory and Human Research Ethics Committee (HREC) submission plans.

These activities support the Company’s preparations for the next phase of clinical development, with particular emphasis on finalizing the documentation, operational infrastructure and regulatory requirements necessary to initiate the proposed study. The Company’s clinical development activities are progressing across several interconnected workstreams:

• Clinical documentation: Preparation of the final clinical protocol and Investigator’s Brochure is ongoing, with final protocol documentation targeted for early November 2026.
• Investigator’s Brochure: Finalization is progressing, with additional stability information relating to clinical samples and the clinical formulation scheduled for incorporation during November.
• Clinical site preparation: Site feasibility and identification activities are progressing well with a first meeting scheduled alongside site budget negotiations and collection of essential regulatory documentation.
• Clinical operations: Vendor selection and contracting activities are progressing, together with the preparation of study plans and clinical data management systems.
• Ethics and regulatory submissions: The current project schedule targets the first-site ethics submission process during November 2026, followed by regulatory activities in January 2027.

The Company currently targets February 2027 for its first clinical site initiation visit followed by its first patient screening, subject to completion of the necessary clinical, regulatory, ethics and operational requirements.

“The continued advancement of these activities represents an important step towards transitioning PPC-001 from preclinical development into clinical evaluation in patients with advanced cancer,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We are contacting multiple sites across Australia, and providing prospective clinical investigators a single, source-traceable account of the scientific rationale and the non-clinical and prior clinical evidence supporting PPC-001, together with the strategy for the proposed First-In-Human Study. I am pleased to confirm that we are fielding strong interest in participating in and acting as lead investigators to support the HREC for the world-first investigation into PPC-001 as a long-term therapy for the treatment and prevention of metastatic cancer. The Propanc management team are expending every effort to rapidly progress PPC-001 into the clinic, and these near-term milestones are expected to be transformative for the Company, its shareholders and ultimately, we hope for patients and their families as well.”

What is PRP and are proposing:

• Investigational product: PRP, trypsinogen and chymotrypsinogen A in a fixed 1:6 ratio (w/w), once weekly intravenous infusion; drug substances naturally derived.
• Therapeutic hypothesis: Not cytotoxic. Differentiation of the malignant phenotype, depletion of the stem-like subpopulation and modification of the tumor stroma.
• Lead indication: Pancreatic ductal adenocarcinoma; US FDA Orphan Drug Designation status achieved in pancreatic cancer.
• Proposed study: Phase 1b, multicenter, open-label, two-part dose escalation and expansion in advanced or metastatic solid tumors.
• Design logic: Backfill Bayesian optimal interval escalation; recommended dose selected on toxicity, delivered dose intensity, exposure and target engagement; expansion at up to two doses.
• Prior human experience: 46 patients given the predecessor proenzyme formulation JBp1 under a UK Specials License Scheme.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

Company plans to explore botanical approval pathways before initiating a prescription drug development program

WASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi (USM) to assess the therapeutic potential of castanospermine—a naturally occurring iminosugar derived from the Australian Chestnut (Castanospermum australe)—in nonclinical models of alpha-gal syndrome (AGS).

The partnership leverages USM’s established vector biology research expertise and investigator insights into tick-borne disease. Under this agreement, 60 Degrees will underwrite the research and retains an option to commercialize and market any resulting intellectual property.

As part of its development strategy, the Company plans to explore potential botanical approval pathways for a castanospermine-containing product before embarking on a prescription drug (Rx) development program. The nonclinical research at USM is expected to help inform this assessment and guide subsequent development decisions.

AGS is an increasingly recognized tick-associated allergic condition, most commonly linked in the United States to bites from the lone star tick. AGS can cause severe and potentially life-threatening allergic reactions following ingestion of, or exposure to, products containing galactose-α-1,3-galactose (alpha-gal), a carbohydrate found in most non-primate mammalian meat and other mammalian-derived products, including beef, pork, lamb, and certain dairy products. Humans do not produce alpha-gal and may develop antibodies against it following tick exposure. There are currently no FDA-approved medications specifically indicated to treat or prevent AGS, and current condition management relies primarily on avoidance of foods and other products that trigger allergic reactions.

About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company obtained U.S. Food and Drug Administration approval of its lead product, ARAKODA^® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA^® or other regimen), castanospermine or celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:
Kristen Landon
kristenlandon@60degreespharma.com

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) — Eco Depot, Inc. (OTCID: ECDP) (“Eco Depot” or the “Company”) today highlighted the infrastructure track record of its wholly-owned construction subsidiary, Compañía Constructora de Tijuana, S.A. de C.V. (“CCT”), including approximately MXN 150 million (US$8.6 million) in selected contracts tied to two of Mexico’s most prominent public works: the Olmeca Refinery at Dos Bocas and the Tren Maya railway.

The Company also outlined the next phase of its plan to build a stronger corporate foundation, beginning with a full review of its capital structure and a search for a PCAOB-registered independent auditor.

An Operating Business with Real Credentials

Since acquiring CCT in January 2024, Eco Depot has centered its strategy on CCT’s construction and infrastructure capabilities. That choice gives the Company an established operating history and a portfolio of work on projects that demanded industrial scale, technical skill and specialized contractors.

Two of Mexico’s Landmark Projects

The Olmeca Refinery at Dos Bocas, in Paraíso, Tabasco, is designed to process 340,000 barrels of crude oil per day and represents a reported investment of about US$16.8 billion. The Tren Maya is a 1,554 kilometer railway connecting 34 stations across five states in southeastern Mexico.

CCT performed the following work on these projects:

Dos Bocas Refinery: approximately MXN 80 million across two contracts. CCT built drainage ditches supporting stormwater management at the refinery and, under a separate contract, treated the water-based bentonite drilling mud generated during construction. Together, these contracts show CCT’s range, from conventional civil construction to specialized environmental services.

Tren Maya: approximately MXN 70 million. CCT built ballast storage platforms that served as staging areas for receiving and storing the ballast required to lay track, reflecting its experience in transportation infrastructure and large-scale construction logistics.

What It Means for Eco Depot

Credentials earned on projects of this profile matter when competing for future work. CCT’s experience positions it to pursue international opportunities in civil construction, industrial infrastructure, transportation, environmental services and related sectors, with a focus on commercially attractive projects. Historical contract values do not represent current backlog or future revenue; they illustrate the type and scale of work CCT has performed.

Building a Stronger Corporate Foundation

Management will undertake a comprehensive review of Eco Depot’s corporate and capital structure, designed to make the Company’s records accurate, consistent and transparent. The review will cover three areas:

• Capital structure: reviewing the Company’s capitalization and verifying historical share issuances.
• Debt and convertible instruments: reviewing and reconciling outstanding obligations and convertible securities.
• Corporate records: confirming that corporate filings, including applicable Secretary of State records, are current and accurate.
• Management views this review as an essential step toward earning shareholder confidence and supporting responsible growth.

Charting a Path in the Capital Markets

Eco Depot is currently evaluating qualified PCAOB-registered independent audit firms, with the objective of engaging an auditor to support its financial reporting and longer-term capital markets strategy. As this work progresses, management will assess opportunities to strengthen the Company’s public market standing, including improved financial reporting practices and applicable reporting compliance; potential eligibility for the OTCQB Venture Market or OTCQX Best Market; and, over the longer term, the feasibility of a national securities exchange listing, subject to meeting all applicable financial, governance, shareholder and regulatory requirements.

These initiatives remain under evaluation. No audit engagement, market tier upgrade or exchange listing has been completed or assured.

Leadership Perspective

“Eco Depot is grounded in real operating achievements,” said Hadelin Carlos Diericx Trouyet, President of Eco Depot, Inc. “CCT has performed work on two of the most significant infrastructure projects in Mexico’s recent history, and that experience anchors our growth strategy. Our task now is to pair it with a corporate foundation investors can trust: accurate records, audited financials and a clear path in the capital markets. We intend to earn the confidence of the ECDP shareholder community through disciplined execution, accountability and measurable progress.”

Investors can expect updates as material developments occur.

About Eco Depot, Inc.

Eco Depot, Inc. (OTCID: ECDP) is developing its operating business through its construction subsidiary, Compañía Constructora de Tijuana, S.A. de C.V. (CCT), which provides civil construction, industrial infrastructure, engineering and environmental services and has supported major infrastructure projects in Mexico.

For more information, visit www.ecdp.co and www.grupocct.mx

Forward-Looking Statements

This press release contains forward-looking statements concerning Eco Depot’s business strategy, corporate governance initiatives, potential auditor engagement, future contracts, financial reporting objectives, potential OTC market-tier upgrades and possible future exchange listings. These statements involve risks and uncertainties and are not guarantees of future performance. Historical contract values do not represent current revenue, profitability or backlog. Actual results may differ materially from expectations. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

Currency note: U.S. dollar equivalents are approximate and calculated at MXN 17.5 per US$1 for illustrative purposes. Actual exchange rates at the dates of the contracts may have differed.

Contact Information:

Eco Depot Inc.
Website: https://ecdp.co/
Email: info@ecdp.co

Latest milestone incorporates advanced sensor data from GEO to strengthen missile warning and tracking

*FORGE, developed by SciTec, combines data from multiple sensors to help Space Force Guardians detect, track, and analyze threats

BOULDER, Colo., Oct. 28, 2026 (GLOBE NEWSWIRE) — SciTec, a Firefly Aerospace company, today announced an operational milestone for the U.S. Space Force’s Space Systems Command (SSC) System Delta 84 Future Operationally Resilient Ground Evolution (FORGE) system developed by SciTec. The latest milestone incorporates data from the SSC’s Wide Field of View space vehicle in geostationary Earth orbit (GEO) and expands the system’s observational reach to strengthen missile warning and defense.

The Wide Field of View sensor provides Overhead Persistent Infrared (OPIR) coverage in support of acquisitional, operational, and research and development priorities of the U.S. Space Force. Key data products have been integrated into FORGE, providing persistent wide-area situational awareness and augmenting time-critical detection capability in conjunction with the data SciTec is processing from other missile warning and tracking satellites.

“SciTec continues to advance FORGE as a modern and scalable system that is capable of ingesting and processing data from legacy and modernized third party sensors,” said David Simenc, SciTec’s President. “We’re using AI and machine learning to ingest and process massive streams of data across all orbits in real time. The integration of this advanced GEO data further expands the field of view for operators and enhances their ability to quickly detect, track, and analyze threats.”

SciTec is delivering this new capability directly into the operational workflows for Space Force Guardians. This capability further demonstrates the benefit of the modern, open architecture of the FORGE system to readily ingest new OPIR mission data and support time‑critical mission needs.

This latest milestone advances SciTec’s $259 million FORGE Enterprise OPIR Solution (EOS) contract to provide advanced mission software that transforms raw OPIR sensor data into actionable insights. Running natively within the FORGE framework, SciTec’s applications enable rapid integration of new data streams and support the U.S. Space Force’s evolving OPIR mission needs.

The milestone builds on SciTec’s initial success during FORGE’s second operational acceptance in September 2025, which fully transitioned operations (mission data processing and framework services), and further demonstrates FORGE’s ability to scale without requiring infrastructure changes. This flexibility is central to FORGE’s design and essential for supporting the next generation of missile warning and battlespace awareness missions.

About SciTec
SciTec, a wholly owned subsidiary of Firefly Aerospace, is a leader in advanced defense technologies. Headquartered in Princeton, N.J., SciTec has more than four decades of experience supporting high-stakes national security missions with AI-enabled defense software and cloud-based, on-premise, and edge processing capabilities. SciTec’s industry-leading software and big data processing capabilities are proven in operations for missile warning and defense; intelligence, surveillance and reconnaissance; space domain awareness; remote sensing and analysis; and autonomous command and control. For more information, visit www.scitec.com.

About Firefly Aerospace
Firefly Aerospace is a space and defense technology company on a mission to reliably and repeatedly launch, land, and operate space systems from Earth to the Moon and beyond. As the partner of choice for responsive space missions, Firefly is the first commercial company to launch a satellite to orbit with approximately 24-hour notice and the first to achieve a successful landing on the Moon. Established in 2017, Firefly’s engineering, manufacturing, and test facilities are co-located in central Texas to enable rapid innovation and vertical integration for the company’s small- to medium-lift launch vehicles, lunar landers, and orbital vehicles. For more information, visit www.fireflyspace.com.

Forward-Looking Statements
This press release contains “forward-looking statements” including, but not limited to, statements regarding the FORGE system and its expected benefits, detection capabilities, the system’s observational reach, statements of SciTec’s Executive Director FORGE programs, and our future expectations, beliefs, plans, objectives, financial conditions, assumptions, future events, or performance that are not historical facts. In some cases, you can identify forward-looking statements because they contain words such as “demonstrates,” “expands,” “enhances,” “may,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “intends,” “believes.” There may also be negative words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Not all forward-looking statements contain such identifying words. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates, or expectations will be achieved.

Various risks that could cause actual results to differ from those expressed by the forward-looking statements included in this press release include, but are not limited to: our failure to manage our growth effectively, including the increasing technological complexity of our business, and our ability to achieve and maintain profitability; the potential for delayed or failed launches, and any failure of our launch vehicles and spacecraft to operate as intended; our inability to deliver software on time or of a quality that our customers demand; the hazards and operational risks that our products and service offerings are exposed to, including the wide and unique range of risks due to the unpredictability of space; the inability to realize our backlog; the fluctuation of our operating results; adverse publicity stemming from any incident involving us, our competitors, or our customers; the failure to adequately protect our proprietary intellectual property rights; our inability to comply with our contractual obligations; and other risk factors set forth in our filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. These statements are based on management’s current expectations, assumptions, and beliefs concerning future developments, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. We cannot assure you that the events reflected in the forward-looking statements will occur; actual events could differ materially from those described in the forward-looking statements. We undertake no intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contacts
press@scitec.com
press@fireflyspace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cfb2957b-6415-4afa-8e75-f5eb323eb081

THORNTON, Colo., Oct. 28, 2026 (GLOBE NEWSWIRE) — Ascent Solar Technologies, Inc. (“Ascent” or the “Company”) (Nasdaq: ASTI), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today announced its participation as co-host of an executive networking event held October 20, 2026, in Willow Springs, California. The event brought together leaders and innovators from across the commercial space industry to discuss emerging technologies, mission requirements and opportunities for future collaboration.

Ascent leadership, including CEO Paul Warley, Chairman of the Board David Peterson and Director of Strategic Sales Tom Bawol, liaised with executives and representatives from various organizations including Venturi Astrolab, Impulse Space, Breakwater Strategies, Sophia Space and others. These discussions showcased Ascent’s thin-film PV technology and its ability to help meet modern space mission power needs to organizations that are actively developing next-generation space technology.

As commercial space missions expand their reach into increasingly ambitious projects, like orbital data centers, lunar exploration and advanced spacecraft platforms, the demand for lightweight, reliable and high-performance power generation solutions grows larger. This demand positions Ascent’s flexible solar technology as a reliable, readymade solution to support these evolving mission needs, as it offers significant advantages in mass reduction, design flexibility and integration versatility.

“Space innovation is accelerating rapidly. As that exponential growth occurs, so too does the fundament need for reliable, efficient power generation to enable the next generation of missions,” said Paul Warley, CEO of Ascent Solar Technologies. “Directly engaging with the very organizations that are shaping the future of space allows us to better understand their evolving needs while also demonstrating how Ascent’s technology can help power their ambitions. The connections established during this event have led to ongoing relationships and discussions that could lead to future revenue that would expand the role our flexible solar solutions play throughout the space industry.”

Ascent’s fully U.S.-manufactured solar solutions and secure domestic supply chain differentiate the Company within an industry that is increasingly focused on supply chain resilience and alignment with U.S. government and defense procurement requirements. These domestic manufacturing capabilities position Ascent to readily support both commercial space innovators and government programs in swift need of reliable solar power technologies.

About Ascent Solar Technologies, Inc.

Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels, optimized for use in space, military and defense, and other applications where mass, performance, reliability, and resilience are paramount.

Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado.

To learn more, visit https://www.ascentsolar.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” including statements about the financing transaction, our business strategy, and the potential uses of the proceeds from the transaction. Such statements also include, but are not limited to, statements related to the intended use of proceeds from the offering and the potential exercise of the series warrants. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the company’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. We have based these forward-looking statements on our current assumptions, expectations, and projections about future events. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “will,” “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,” “plan,” to be uncertain and forward-looking. No information in this press release should be construed as any indication whatsoever of our future revenues, stock price, or results of operations. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company’s filings with the Securities and Exchange Commission including those discussed under the heading “Risk Factors” in our most recently filed reports on Forms 10-K and 10-Q.

Media Contact

Spencer Herrmann
FischTank PR
Ascent@FischTankPR.com

MARLBOROUGH, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) — ConnectM Technology Solutions, Inc. (OTCQX: CNTM) (“ConnectM” or the “Company”), a U.S.-based technology company that develops, sells and operates energy infrastructure powering the physical layer of the AI economy, today announced the appointment of Leonardo (“Leo”) Riera to its Board of Directors as Lead Independent Director, effective October 21, 2026. Mr. Riera brings more than 40 years of investment banking and international capital markets experience, including more than 10 years as Country Head of Bankers Trust in Venezuela, and serves on three boards, including Sidus Space, Inc. (NASDAQ: SIDU), where he is a director and former Chairman.

As Lead Independent Director, Mr. Riera will preside over sessions of the independent directors and serve as their principal liaison to the Chairman. He will also serve on the Board’s Audit and Compensation Committees and will chair the Nominating and Corporate Governance Committee. The Board has been expanded from five to six members.

Bhaskar Panigrahi, Chairman and Chief Executive Officer of ConnectM, commented, “Leo’s appointment strengthens ConnectM’s corporate governance. He has spent four decades in capital markets and M&A, has chaired the board of a Nasdaq-listed company and the audit committees of others, and has led the consolidation and financing of businesses from the board seat. His independent perspective will help us evaluate growth opportunities, strengthen financial oversight and build long-term value for shareholders.”

Mr. Riera currently serves on the boards of Sidus Space, a space and defense technology company, where he previously served as Chairman; Katmai Tech, Inc., a software company, where he is Audit Committee Chair; and FenixOro Gold, a mining exploration company, where he is also Audit Committee Chair. He also advises the Chairman and Chief Executive Officer of a semiconductor company. Earlier, he conceived and led the consolidation of sixteen companies into a single Colorado-based enterprise and served as a director and Audit Committee Chairman of the combined company.

From 1988 to 1998, Mr. Riera was Executive Director and Country Head of Bankers Trust Company in Venezuela, where he founded and led the firm’s investment banking and broker-dealer operations with full profit-and-loss responsibility and oversaw M&A, capital markets, private equity and advisory transactions across the oil, mining, electric, telecom, banking and retail sectors. Fee generation quadrupled during his tenure. Before Bankers Trust, he was Head of M&A at Citicorp Investment Bank in Venezuela and a McKinsey & Company consultant on the restructuring of Petróleos de Venezuela, then the world’s third-largest oil company. He later served as Head of Asset Structuring and Credit at INTL Consilium, an emerging-markets investment fund whose assets under management grew from approximately $500 million to $2.1 billion during 2007.

Mr. Riera also has direct energy operating experience. He co-founded EnviroPower Renewable, Inc. and served as its Chairman and Chief Executive Officer from 2012 to 2018, developing waste-to-energy projects in the United States, Ireland and the United Kingdom and raising all of the company’s development capital. He served three consecutive terms as President of the Foreign Banks Association of Venezuela. He holds an MBA in Finance and International Management from the Wharton School of the University of Pennsylvania and a Bachelor of Science in Economics from Universidad Católica Andrés Bello, where he graduated first in his class, and completed the Strategic Valuations executive program at Harvard Business School.

“I have spent my career on both sides of capital markets transactions and on the boards of companies at important stages of growth. ConnectM is at an inflection point as it evolves into a focused AI energy infrastructure company,” said Mr. Riera. “The Blue Cloud transaction showed that this management team can realize value as well as build it. I look forward to working with Bhaskar and the Board to strengthen governance, financial oversight and capital allocation and to create long-term shareholder value.”

About ConnectM Technology Solutions, Inc.

ConnectM Technology Solutions, Inc. (OTCQX: CNTM) is a U.S.-based AI energy infrastructure company that integrates and operates the power, thermal and intelligence systems beneath AI compute. Its power offerings include battery storage, solar and distributed energy systems, and virtual power plant dispatch. Its thermal offerings include smart heat pumps sold through enterprise distributors. Its wholly owned subsidiary, Keen Labs, develops the AI platform for monitoring, energy optimization and predictive maintenance across connected equipment. ConnectM is evaluating distributed compute as an asset-light alternative to traditional data centers, with the Company supplying power, site access and orchestration and compute partners providing and operating the hardware. ConnectM is headquartered in Marlborough, Massachusetts. For more information, visit www.connectm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. All statements, other than statements of present or historical fact included in this press release, regarding our future financial performance, our strategy, the proposed listing of our common stock on a national securities exchange, the Ascent financing and the repayment, amortization or conversion of outstanding notes, the objectives and expected contributions of our Board, the contemplated divestiture of our Owned Service Network operations, expansion plans, future operations, future operating results, estimated revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “continue,” “project” or the negative of such terms or other similar expressions. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements, including the risks described in the “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” sections of our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including that our financial statements include a going concern explanatory paragraph, that our application to list on a national securities exchange may not be approved, and that the value of our Blue Cloud shareholding, which is subject to a lock-up, may fluctuate significantly.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ConnectM is under no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts

Investor Relations
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: CNTM@crescendo-ir.com

ConnectM Technology Solutions, Inc.
+1 617-395-1333
irpr@connectm.com

• The ‘Ms. Represented’ campaign expands its reach with professional snowboarder Chloe Kim, who shares her ADHD experience to help connect with a younger generation of women.
• More than 60% of U.S. women who reported ever receiving an ADHD diagnosis were first diagnosed in adulthood, underscoring the importance of recognizing experiences that don’t fit familiar perceptions of the condition.¹
• Chloe is partnering with Qelbree, the #1 prescribed branded non-stimulant ADHD medication as of May 2026 which has reached approximately 3 million prescriptions filled since launch in 2021.*

ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) — Professional snowboarder Chloe Kim is bringing her personal attention-deficit/hyperactivity disorder (ADHD) journey to ‘Ms. Represented,’ a campaign from Supernus Pharmaceuticals for Qelbree (viloxazine extended-release capsules), a once-a-day, non-stimulant ADHD treatment for people ages 6 years and older. Diagnosed with ADHD as an adult, Chloe didn’t recognize her own experience in familiar portrayals of ADHD. Now, as a paid spokesperson for Supernus, she is opening up about her journey to change the conversation and help other women feel seen, understood, and represented.

Launched last year, the ‘Ms. Represented’ campaign challenges the narrow perceptions of ADHD that can leave women feeling misrepresented. Boys are nearly twice as likely as girls to be diagnosed with ADHD, while the percentage of women ages 23–49 newly diagnosed with the condition nearly doubled between 2020 and 2022.^2,3 While ADHD is often associated with hyperactivity and impulsivity, it can also involve inattentive symptoms, including less visible experiences such as getting easily distracted or having difficulty with organization.⁴ For Chloe, recognizing patterns in her own experiences helped her better understand her ADHD diagnosis, bringing another perspective to the campaign and helping connect with a younger generation of women.

“When I was diagnosed with ADHD, so much about what I had been experiencing finally made sense,” said Chloe. “I hope that by sharing my story, more women feel empowered to ask questions, seek support, and know that having ADHD doesn’t limit what they’re capable of achieving.”

Following Chloe’s diagnosis, she explored treatment options with her doctor and now takes once-a-day, non-stimulant Qelbree to help manage her ADHD symptoms. Initially approved for children ages 6-17 years in April 2021 and subsequently for adults in April 2022, Qelbree offers a treatment option for the nearly 16 million adults and 7 million adolescents living with ADHD in the U.S.^5,6

“Through the ‘Ms. Represented’ campaign, we’re continuing to challenge the misconceptions that have left women’s experiences with ADHD overlooked for too long,” said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “Chloe brings an important perspective to that mission, and as we mark five years of Qelbree, we remain committed to raising awareness and providing a non-stimulant treatment option to help people manage their ADHD symptoms.”

Designed to inspire action, the ‘Ms. Represented’ campaign meets women where they are, using engaging storytelling to spark vital health conversations. By connecting the dots across her passions, from snowboarding, fashion to mental health, Chloe brings the initiative to life in editorial collaborations with Coveteur and PureWow, alongside an appearance on a social-first episode of Are You Okay?.

To learn more about Chloe’s story and the ‘Ms. Represented’ campaign, visit www.qelbree.com/msrepresented. For more information about Qelbree, visit www.qelbree.com.

*Qelbree’s pediatric indication was approved for children ages 6-17 years in April 2021.

INDICATION

Qelbree^® (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION

Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You or your child should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed Warning, and Medication Guide here.

Qelbree (viloxazine extended-release capsules) is available in 100 mg, 150 mg and 200 mg capsules.

About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.

For more information, please visit www.supernus.com.

Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc.
©2026 Supernus Pharmaceuticals, Inc. All rights reserved.

1. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics Rapid Surveys System, Round 2: ADHD. October–November 2023. https://www.cdc.gov/nchs/rss/round2/adhd.html   
2. Reuben C., Elgaddal N. (2024) Attention-deficit/hyperactivity disorder in children ages 5–17 years: United States, 2020–2022. NCHS Data Brief, no 499. Hyattsville, MD: National Center for Health Statistics.
3. Russell, J., et al. (2023). Number of ADHD Patients Rising, Especially Among Women. Epic Research.
4. Quinn, P.O. and Madhoo, M. (2014). A Review of Attention Deficit/Hyperactivity Disorder in Women and Girls: Uncovering This Hidden Diagnosis. Prim Care Companion CNS Disord.
5. Centers for Disease Control and Prevention (CDC). ADHD in Adults: An Overview. October 8, 2024. https://www.cdc.gov/adhd/articles/adhd-across-the-lifetime.html
6. CDC. Data and Statistics on ADHD. November 19, 2024. https://www.cdc.gov/adhd/data/index.html

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

Or

INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com

Or

MEDIA CONTACT:
Diana Torres-Bixby
Burson
(917) 686-0517
diana.torres-bixby@bursonglobal.com

QBE.2026-0317